Verrica Pharmaceuticals to report Q1 2026 financial results and corporate update on May 12

Verrica Pharmaceuticals announced it will release its financial results for the first quarter ending March 31, 2026, on May 12, 2026. The company will hold a conference call and webcast to discuss the results and provide a corporate update. Verrica specializes in dermatological treatments, including its FDA-approved product YCANTH® for molluscum contagiosum and ongoing development of treatments for warts and non-melanoma skin cancers. Investors can access the live call via phone or webcast, with a replay available for 90 days on the company website.